Not a good buy right now for an impatient investor: momentum is still bearish (MACD worsening) and price is trading below key support zones.
The only near-term “bull case” is a potential oversold bounce near S2 (6.106), but there’s no Intellectia signal confirming an entry and insider selling is heavy.
Trend/Momentum: Bearish. MACD histogram is negative (-0.0816) and expanding lower, indicating downside momentum is strengthening.
RSI: RSI(6) at ~28 is effectively oversold, which can fuel a short-term bounce, but oversold alone is not a buy signal while MACD is deteriorating.
Moving averages: Converging MAs suggest price is compressing/trying to base, but not yet confirming reversal.
Levels: Current price 6.26 is below S1 (6.465) and above S2 (6.106). This puts the stock in a fragile zone—break below ~6.11 risks another leg down; reclaiming 6.47 is the first step to stabilization.
Near-term pattern odds (similar candlesticks): next week ~flat, next month modestly positive (+5.12%), but with weak day-to-day confidence.
Options Data
Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio
Sentiment is mixed-to-bearish: Open Interest P/C = 0.73 (more calls open than puts → mildly constructive positioning), but Volume P/C = 7.0 (puts dominated today’s trading → bearish/defensive flow).
Volatility: IV30 ~86.45 vs historical vol ~46.51 implies options are priced rich; market is expecting larger moves than recent realized action.
IV trend: IV 5D avg (72.5) < current (86.5) suggests volatility has been rising recently.
Liquidity/activity: Today’s option volume (80) is below the 10D avg (~146), so today’s put-heavy skew may be less reliable than if volume were elevated.
Technical Summary
Sell
7
Buy
5
Positive Catalysts
near S2 (6.
can trigger a reflex bounce.
Neutral/Negative Catalysts
with risk of testing/breaking S2 (6.106).
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 17.497M, up ~11.97% YoY (solid top-line growth).
Net income: 1.45M, up ~879.73% YoY (major profitability improvement).
EPS: 0.05, ~0.00% YoY (EPS not showing the same improvement as net income—suggests dilution/share count effects or other accounting items).
Gross margin: 72.94%, up ~3.55% YoY (healthy and improving margins).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating/price target change data was provided, so there’s no clear read on recent Wall Street upgrades/downgrades.
Wall Street-style pros (based on provided fundamentals): improving revenue growth, sharply higher net income, expanding gross margin.
Wall Street-style cons (based on provided positioning/flow): heavy insider selling, bearish price action/weak momentum, and put-heavy options volume suggests caution near-term.
Influential/political flows: No recent congress trading data available; hedge funds are described as neutral.
Wall Street analysts forecast CXDO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CXDO is 8.9 USD with a low forecast of 8 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast CXDO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CXDO is 8.9 USD with a low forecast of 8 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.245
Low
8
Averages
8.9
High
10
Current: 6.245
Low
8
Averages
8.9
High
10
Northland
Michael Latimore
Outperform
maintain
$8 -> $10
AI Analysis
2025-11-05
Reason
Northland
Michael Latimore
Price Target
$8 -> $10
AI Analysis
2025-11-05
maintain
Outperform
Reason
Northland analyst Michael Latimore raised the firm's price target on Crexendo to $10 from $8 and keeps an Outperform rating on the shares after a "strong quarter across the board" that featured double-digit revenue and backlog growth along with "record" adjusted EBITDA margins.
B. Riley
Buy
upgrade
$8
2025-11-05
Reason
B. Riley
Price Target
$8
2025-11-05
upgrade
Buy
Reason
B. Riley raised the firm's price target on Crexendo to $8 from $7.50 and keeps a Buy rating on the shares. The company another strong quarter as its artifificail intelligence monetization takes shape, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CXDO
